Detection of early liver cancer kit approved clinical use

        Beijing October 19th news (reporter Wan Yufeng) liver cancer patients today ushered in good news. The tumor marker heat shock protein 90 alpha (Hsp90) kit, developed by Luo Yongzhang team of Tsinghua University, has been approved by the State Food and Drug Administration for clinical use. The kit only needs a small amount of blood, can detect early liver cancer, lung cancer, can comprehensively improve the level of prevention and treatment of liver cancer, reduce the mortality rate.

        In 2013, Tsinghua University, the National Engineering Laboratory of anti tumor protein drugs through lung cancer clinical trials, to prove that the plasma Hsp90 alpha is a new tumor markers. The State Food and Drug Administration approved the use of plasma Hsp90 alpha as a liver cancer marker, marking the first by the Chinese scientists defined and approved for the clinical use of a broad spectrum of tumor markers. At present, the majority of patients with hepatocellular carcinoma found in the middle and late, survival is expected to generally poor. AFP is recognized as a marker for liver cancer detection, sensitivity is only about 50%. The Hsp90 alpha breaks through the limitations of AFP.